Exclusive Perpetual Licenses - Apollon Patents & IP

Global Hemp Group has acquired the exclusive perpetual license for North America (the United States, Canada and Mexico) to certain Apollon Intellectual Property and proprietary technology, including, but not limited to, four key patents including any continuations, divisional, and continuations-in-part, along with any and all associated preclinical and clinical data relating to the patents and proprietary technology (the “IP”). The Exclusive Licensing has since been expanded for the two Composition patents listed below to include the European Union with extension to Morocco and Israel.

These patents include claims to the treatments of cancers and inflammatory conditions using natural biologics including compounds in medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds that have been shown in independent, third-party preclinical 3D cell culture testing to kill cancer cells via direct cytotoxicity and immune stimulated cytotoxicity with great success and high efficacy. Under the Exclusive License Agreement, GHG will have the right to sublicense this intellectual property to Pre-Clinical Validation of Cannabinoid and Mushroom Preparations for the Treatment of Cancer published January 31, 2024 on the Online Journal of Complementary & Alternative Medicine, an international peer review journal that aims to bring the ancient traditional methods to the world and its importance to the people. Apollon Formularies Plc is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including cannabinoids, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, thirdparty results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform. ABOUT US PROJECTS NEWS INVESTORS CONNECT legally licensed producers, and will initially focus on the United States (state by state where medicinal cannabis is legal) and Canada, allowing for the opportunity to generate near-term sublicensing revenue in these two countries

The Company is now engaged in discussions with legally licensed manufacturers, distributors and retail partners in the United States and Canada to monetize this IP by sublicensing it on both an exclusive and nonexclusive basis. To assist the Company in achieving this goal of creating an ongoing revenue stream, GHG has engaged Dr. Stephen D. Barnhill MD, creator of the IP and Chairman & CEO of Apollon, as Special Medical Advisor to the Company.

The Markets for the individual compounds used in the Apollon combinatorial pharmaceuticals are provided below.